Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• BRAF V600E/K mutations drive melanoma, but resistance to BRAF/MEK inhibitors (BRAFi/MEKi) limits efficacy.
• Acquired resistance mechanisms, including RAF dimerization, and brain metastasis are significant challenges in melanoma treatment.

Purpose of the Study:

• To develop and characterize a novel BRAF inhibitor (Compound Ia) designed to overcome resistance to existing BRAFi/MEKi therapies.
• To evaluate Compound Ia's efficacy in preclinical models of melanoma, including those with acquired resistance and brain metastases.

Main Methods:

• Comprehensive in vitro, ex vivo, and in vivo preclinical characterization of Compound Ia.
• Evaluation in melanoma models with BRAF V600E/K mutations, acquired resistance, and brain metastasis.
• Assessment of Compound Ia's potency, selectivity, paradoxical activation inhibition, and CNS penetration.

Main Results:

• Compound Ia demonstrated high potency and selectivity, inhibiting BRAF-mutant cells without paradoxical activation.
• It showed superior efficacy compared to approved BRAFi and BRAFi/MEKi combinations in various preclinical models.
• Compound Ia exhibited significant central nervous system (CNS) penetration and outperformed approved BRAFi in brain metastasis models.

Conclusions:

• Compound Ia is a novel, brain-penetrant BRAF inhibitor with preclinical potential to overcome resistance to current targeted therapies.
• Its efficacy in BRAF-mutant melanoma, including brain metastases and resistant models, warrants further clinical investigation.